Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
- 10 February 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (580)
- https://doi.org/10.1126/scitranslmed.abd3438
Abstract
Nucleic acids are used in many therapeutic modalities, including gene therapy, but their ability to trigger host immune responses in vivo can lead to decreased safety and efficacy. In the case of adeno-associated viral (AAV) vectors, studies have shown that the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA. Here, we engineered AAV vectors to be intrinsically less immunogenic by incorporating short DNA oligonucleotides that antagonize TLR9 activation directly into the vector genome. The engineered vectors elicited markedly reduced innate immune and T cell responses and enhanced gene expression in clinically relevant mouse and pig models across different tissues, including liver, muscle, and retina. Subretinal administration of higher-dose AAV in pigs resulted in photoreceptor pathology with microglia and T cell infiltration. These adverse findings were avoided in the contralateral eyes of the same animals that were injected with the engineered vectors. However, intravitreal injection of higher-dose AAV in macaques, a more immunogenic route of administration, showed that the engineered vector delayed but did not prevent clinical uveitis, suggesting that other immune factors in addition to TLR9 may contribute to intraocular inflammation in this model. Our results demonstrate that linking specific immunomodulatory noncoding sequences to much longer therapeutic nucleic acids can "cloak" the vector from inducing unwanted immune responses in multiple, but not all, models. This "coupled immunomodulation" strategy may widen the therapeutic window for AAV therapies as well as other DNA-based gene transfer methods.Keywords
Funding Information
- National Institutes of Health (RM1 HG008525)
- National Institutes of Health (EY026158)
- Howard Hughes Medical Institute
- National Eye Research Centre (BRI 021)
- European Research Council (ERC-CoG-617432)
- Wyss Institute for Biologically Inspired Engineering of Harvard University
- Underwood Trust (8064)
- Kentucky Lions Eye Research Endowed Chair
- Ally Therapeutics
This publication has 47 references indexed in Scilit:
- AAV cis -regulatory sequences are correlated with ocular toxicityProceedings of the National Academy of Sciences of the United States of America, 2019
- Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremiaNature Medicine, 2018
- Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal DeliveryMolecular Therapy, 2018
- Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta ExperienceAmerican Journal of Ophthalmology, 2018
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMNHuman Gene Therapy, 2018
- The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J MiceMolecular Therapy, 2018
- Single-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyThe New England Journal of Medicine, 2017
- Long-Term Effect of Gene Therapy on Leber’s Congenital AmaurosisThe New England Journal of Medicine, 2015
- In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the VitreousScience Translational Medicine, 2013
- Gene therapy - promises, problems and prospectsNature, 1997